Abstract
A sparse sampling strategy (3 samples per patient, 521 patients) was implemented in 22 Phase 2 studies of docetaxel (Taxotere®) at the first treatment cycle for a prospective population pharmacokinetic evaluation. In addition to the 521 Phase 2 patients, 26 (data rich) patients from Phase 1 studies were included in the analysis. NONMEM analysis of an index set of 280 patients demonstrated that docetaxel clearance (CL) is related to α1-acid glycoprotein (AAG) level, hepatic function (HEP), age (AGE), and body surface area (BSA). The index set population model prediction ofCL was compared to that of a naive predictor (NP) using a validation set of 267 patients. Qualitatively, the dependence ofCL onAAG, AGE, BSA, andHEP seen in the index set population model was supported in the validation set. Quantitatively, for the validation set patients overall, the performance (bias, precision) of the model was good (7 and 21%, respectively), although not better than that of theNP. However, in all the subpopulations with decreasedCL, the model performed better than theNP; the more theCL differed from the population average, the better the performance. For example, in the subpopulation of patients withAAG levels>2.27 g/L (n=26) bias and precision of model predictions were 24 and 32% vs. 53 and 53%, respectively, for theNP. The prediction ofCL using the model was better (than that of theNP) in 73% of the patients. The population model was redetermined using the whole population of 547 patients and a new covariate, albumin plasma level, was found to be a significant predictor in addition to those found previously. In the final model,HEP, AAG, andBSA are the main predictors of docetaxelCL.
Similar content being viewed by others
References
C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman, L. Sanathanan, J. J. Schentag, V. P. Shah, L. B. Sheiner, J. P. Skelly, D. R. Stanski, R. J. Temple, C. T. Viswanashan, J. Weissinger, and A. Yacobi. Opportunities for integration of pharmacokinetics, pharmaco-dynamics and toxicokinetics in rational drug development.Clin. Pharmacol. Ther. 51:465–473 (1992).
L. Aarons, L. P. Balant, F. Mentré, P. L. Morselli, M. Rowland, J. L. Steimer, and S. Vozeh. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software.Eur. J. Clin. Pharmacol. 46:389–391 (1994).
S. Vozeh, P. O. Maitre, and D. R. Stanski. Evaluation of population (NONMEM) pharmacokinetic parameter estimates.J. Pharmacokin. Biopharm. 18:161–173 (1990).
S. L. Beal. Validation of a population model E-mail on the NONMEM Users Network. February 1, 1994.
R. Pazdur, A. P. Kudelka, J. J. Kavanagh, P. R. Cohen, and M. N. Raber. The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®).Cancer Treat. Rev. 19:351–386 (1993).
R. Bruno and G. Sanderink. Pharmacokinetics and metabolism of TaxotereTM.Cancer Surveys 17:305–313 (1993).
R. Bruno, V. Cosson, J. C. Vergniol, G. Montay, N. Le Bail, M. Bayssas, M. Marty, M. Clavel, M. Aapro, P. Alberto, and A. Frydman. Taxotere population pharmacokinetics.Proc. Am. Assoc. Cancer Res. 34:234 (1993) (abstract).
M. C. Launay-Iliadis, R. Bruno, V. Cosson, J. C. Vergniol, D. Oulid-Aissa, M. Marty, M. Clavel, M. Aapro, N. Le Bail, and A. Iliadis. Population pharmacokinetics of docetaxel during Phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.Cancer Chemother. Pharmacol. 37:47–54 (1995).
R. Bruno, M. B. Dorr, G. Montay, A. Frydman, F. This, P. Fumoleau, S. Kay, G. H. Kavanagh, H. A. Burris, J. R. Rigas, and M. Bayssas. Design and prospective implementation of population pharmacokinetic studies during the development of docetaxel (RP 56976), a new anticancer drug.Clin. Pharmacol. Ther. 55:161 (1994) (abstract).
J. C. Vergniol, R. Bruno, G. Montay, and A. Frydman. Determination of Taxatere in human plasma by a semi-automated high-performance liquid chromatographic method.J. Chromatog. 582:273–278 (1992).
S. L. Beal, A. J. Boeckman, and L. B. Sheiner.NONMEM. User's Guide Part I to VI, University of California at San Francisco, San Francisco, 1988–1992.
L. B. Sheiner and S. L. Beal. Some suggestions for measuring predictive performance.J. Pharmacokin. Biopharm. 9:503–512 (1981).
L. B. Sheiner and L. Z. Benet. Premarketing observational studies of population pharmacokinetics of new drugs.Clin. Pharmacol. Ther. 38:481–487 (1985).
P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam.J. Pharmacokin. Biopharm. 19:377–384 (1991).
J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects.J. Pharmacokin. Biopharm. 20:511–528 (1992).
R. Bruno, M.-C. Iliadis, B. Lacarelle, V. Cosson, J. W. Mandema, Y. Le Roux, G. Montay, A. Durand, M. Ballereau, M. Alasia, J. Albanese, G. Francois, A. Iliadis, and A. Frydman. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients.J. Pharmacokin. Biopharm. 20:653–669 (1992).
R. Bruno, D. Hille, L. Thomas, A. Riva, and L. B. Sheiner. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere®) in Phase II studies.Proc. Am. Soc. Clin. Oncol. 14:457 (1995) (abstract).
Author information
Authors and Affiliations
Additional information
On sabbatical leave with Rhône-Poulenc Rorer at time of the study
Rights and permissions
About this article
Cite this article
Bruno, R., Vivier, N., Vergniol, J.C. et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation. Journal of Pharmacokinetics and Biopharmaceutics 24, 153–172 (1996). https://doi.org/10.1007/BF02353487
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02353487